Jialin Meng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4608757/publications.pdf

Version: 2024-02-01

		516561	580701
74	996	16	25
papers	citations	h-index	g-index
87	87	87	1050
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	<i>MOVICS</i> : an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics, 2021, 36, 5539-5541.	1.8	57
2	The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer. Cancer Medicine, 2019, 8, 5202-5213.	1.3	53
3	Immune response drives outcomes in prostate cancer: implications for immunotherapy. Molecular Oncology, 2021, 15, 1358-1375.	2.1	48
4	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications, 2020, 11, 2689.	5 . 8	41
5	Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. Molecular Therapy - Oncolytics, 2021, 20, 410-421.	2.0	38
6	Upregulation of Long Noncoding RNA TUG1 Promotes Bladder Cancer Cell Proliferation, Migration, and Invasion by Inhibiting miR-29c. Oncology Research, 2018, 26, 1083-1091.	0.6	37
7	Systematic investigation of the prognostic value of cell division cycle-associated proteins for clear cell renal cell carcinoma patients. Biomarkers in Medicine, 2020, 14, 223-238.	0.6	37
8	Effect of alcohol on chronic pelvic pain and prostatic inflammation in a mouse model of experimental autoimmune prostatitis. Prostate, 2019, 79, 1466-1476.	1.2	34
9	Rapamycin treatment doseâ€dependently improves the cystic kidney in a new <scp>ADPKD</scp> mouse model <i>via</i> the <scp>mTORC</scp> 1 and cellâ€cycleâ€associated <scp>CDK</scp> 1/cyclin axis. Journal of Cellular and Molecular Medicine, 2017, 21, 1619-1635.	1.6	33
10	<i>TP73 G4C14-A4T14</i> polymorphism and cancer susceptibility: evidence from 36 case–control studies. Bioscience Reports, 2018, 38, .	1.1	31
11	MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system. Biomaterials, 2019, 216, 119248.	5.7	28
12	Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. JCI Insight, 2018, 3, .	2.3	28
13	CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. Pathology Research and Practice, 2019, 215, 151-158.	1.0	25
14	Multiâ€omics consensus ensemble refines the classification of muscleâ€invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies. Clinical and Translational Medicine, 2021, 11, e601.	1.7	25
15	Characterization of the prognostic values and response to immunotherapy/chemotherapy of Krüppelâ€like factors in prostate cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 5797-5810.	1.6	24
16	Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR. Oncogene, 2021, 40, 1674-1689.	2.6	23
17	Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 755212.	1.3	21
18	Tenâ€Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wildâ€Type Isocitrate Dehydrogenase 1. Hepatology, 2021, 73, 1747-1763.	3.6	20

#	Article	IF	CITATIONS
19	Singleâ€cell multiâ€omics analysis presents the landscape of peripheral blood Tâ€cell subsets in human chronic prostatitis/chronic pelvic pain syndrome. Journal of Cellular and Molecular Medicine, 2020, 24, 14099-14109.	1.6	18
20	Polymorphism of MMP-9 gene is not associated with the risk of urinary cancers: Evidence from an updated meta-analysis. Pathology Research and Practice, 2018, 214, 1966-1973.	1.0	17
21	Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer. Genomics, 2020, 112, 4980-4992.	1.3	17
22	Tumour microenvironmentâ€based molecular profiling reveals ideal candidates for highâ€grade serous ovarian cancer immunotherapy. Cell Proliferation, 2021, 54, e12979.	2,4	16
23	Exocyst controls exosome biogenesis via Rab11a. Molecular Therapy - Nucleic Acids, 2022, 27, 535-546.	2.3	14
24	An update meta-analysis and systematic review of TAP polymorphisms as potential biomarkers for judging cancer risk. Pathology Research and Practice, 2018, 214, 1556-1563.	1.0	13
25	<p>Prognostic Role of Prothrombin Time Activity, Prothrombin Time, Albumin/Globulin Ratio, Platelets, Sex, and Fibrinogen in Predicting Recurrence-Free Survival Time of Renal Cancer</p> . Cancer Management and Research, 2020, Volume 12, 8481-8490.	0.9	13
26	Epigenetic age acceleration of cervical squamous cell carcinoma converged to human papillomavirus 16/18 expression, immunoactivation, and favourable prognosis. Clinical Epigenetics, 2020, 12, 23.	1.8	13
27	Effect of polymorphism on IL1A to cancer susceptibility: Evidence based on 34,016 subjects. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 3138-3152.	1.9	12
28	PSMA-targeted arsenic nanosheets: a platform for prostate cancer therapy <i>via</i> ferroptosis and ATM deficiency-triggered chemosensitization. Materials Horizons, 2021, 8, 2216-2229.	6.4	12
29	Integrative analysis the characterization of peroxiredoxins in pan-cancer. Cancer Cell International, 2021, 21, 366.	1.8	12
30	Transparenchymal Renal Pelvis Injection of Recombinant Adeno-Associated Virus Serotype 9 Vectors Is a Practical Approach for Gene Delivery in the Kidney. Human Gene Therapy Methods, 2018, 29, 251-258.	2.1	11
31	Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients. International Journal of Clinical Practice, 2019, 73, e13438.	0.8	11
32	Prognosis stratification and personalized treatment in bladder cancer through a robust immune gene pairâ€based signature. Clinical and Translational Medicine, 2021, 11, e453.	1.7	11
33	Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth. Cancer Letters, 2019, 442, 483-490.	3.2	10
34	Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis. Cytokine, 2021, 141, 155440.	1.4	10
35	Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. Cell Death and Disease, 2021, 12, 855.	2.7	10
36	Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity. Frontiers in Immunology, 2022, 13, 842069.	2.2	10

#	Article	IF	CITATIONS
37	Activated autophagy restored the impaired frequency and function of regulatory T cells in chronic prostatitis. Prostate, 2021, 81, 29-40.	1.2	9
38	Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 723817.	1.8	9
39	Integrated multiâ€omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clinical and Translational Medicine, 2021, 11, e655.	1.7	9
40	Risk subtyping and prognostic assessment of prostate cancer based on consensus genes. Communications Biology, 2022, 5, 233.	2.0	8
41	Do polymorphisms in protein kinase catalytic subunit alpha-1 gene associated with cancer susceptibility? a meta-analysis and systematic review. BMC Medical Genetics, 2018, 19, 189.	2.1	7
42	The prevalence and risk factors of prostatic calculi in Han Chinese: a cross-sectional study based on health examinations. Aging Male, 2020, 23, 887-892.	0.9	7
43	Correlating Transcriptional Networks to Papillary Renal Cell Carcinoma Survival: A Large-Scale Coexpression Analysis and Clinical Validation. Oncology Research, 2020, 28, 285-297.	0.6	7
44	SGK2 promotes renal cancer progression via enhancing ERK 1/2 and AKT phosphorylation. European Review for Medical and Pharmacological Sciences, 2019, 23, 2756-2767.	0.5	7
45	Expression and Prognostic Values of the Roof Plate-Specific Spondin Family in Bladder Cancer. DNA and Cell Biology, 2020, 39, 1072-1089.	0.9	6
46	Multiomics data reveals the influences of myasthenia gravis on thymoma and its precision treatment. Journal of Cellular Physiology, 2021, 236, 1214-1227.	2.0	6
47	Efficacy and safety evaluation of lowâ€intensity extracorporeal shock wave therapy on prostatitisâ€like symptoms: An openâ€label, singleâ€arm trial. Andrologia, 2022, 54, e14260.	1.0	6
48	Nomogram for predicting the overall survival of patients with earlyâ€onset prostate cancer: A populationâ€based retrospective study. Cancer Medicine, 2022, 11, 3260-3271.	1.3	6
49	Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients. International Journal of Medical Sciences, 2021, 18, 284-294.	1.1	5
50	Clinical Features of 167 Inpatients with Autosomal Dominant Polycystic Kidney Disease at a Single Center in China. Medical Science Monitor, 2018, 24, 6498-6505.	0.5	5
51	Identification of novel susceptibility factors related to CP/CPPSâ€like symptoms: Evidence from a multicenter caseâ€control study. Prostate, 2022, 82, 772-782.	1.2	5
52	Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis. Journal of Infection, 2022, 84, 834-872.	1.7	5
53	HA/CD44 Regulates the T Helper 1 Cells Differentiation by Activating Annexin A1/Akt/mTOR Signaling to Drive the Pathogenesis of EAP. Frontiers in Immunology, 2022, 13, .	2.2	5
54	Signature for Prostate Cancer Based on Autophagy-Related Genes and a Nomogram for Quantitative Risk Stratification. Disease Markers, 2022, 2022, 1-22.	0.6	5

#	Article	IF	Citations
55	Harnessing Calciumâ€Oxalate―(CaOxâ€) Nanocrystalâ€Induced Prodeath Autophagy for Attenuating Human Renal Proximal Tubular Epithelial Cell Injury. Particle and Particle Systems Characterization, 2019, 36, 1900083.	1.2	4
56	Development and Validation of the B Cell-Associated Fc Receptor-like Molecule-Based Prognostic Signature in Skin Cutaneous Melanoma. BioMed Research International, 2020, 2020, 1-11.	0.9	4
57	RNA processing genes characterize RNA splicing and further stratify colorectal cancer. Cell Proliferation, 2020, 53, e12861.	2.4	4
58	Specific epigenetic age acceleration patterns among four molecular subtypes of gastric cancer and their prognostic value. Epigenomics, 2021, 13, 767-778.	1.0	4
59	Role of Non-Coding RNA in Neurological Complications Associated With Enterovirus 71. Frontiers in Cellular and Infection Microbiology, 2022, 12, 873304.	1.8	4
60	4â€Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis. Prostate, 2021, 81, 1078-1090.	1.2	3
61	Qualitative Transcriptional Signature for the Pathological Diagnosis of Pancreatic Cancer. Frontiers in Molecular Biosciences, 2020, 7, 569842.	1.6	2
62	Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis. BMC Cancer, 2021, 21, 771.	1.1	2
63	A new nomogram allows doctors to identify high-risk patients with fever after prostate biopsy in advance. Medical Science Monitor, 2020, 26, e921350.	0.5	2
64	Synthetic Circular gRNA Mediated Biological Function of CRISPR-(d)Cas9 System. Frontiers in Cell and Developmental Biology, 2022, 10, 863431.	1.8	2
65	Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients. Medical Science Monitor, 2019, 25, 9991-10007.	0.5	1
66	Macrophages and monocytes mediated activation of oxidative phosphorylation implicated the prognosis and clinical therapeutic strategy of Wilms tumour. Computational and Structural Biotechnology Journal, 2022, 20, 3399-3408.	1.9	1
67	Metabolomics Analysis Reveals the Differential Metabolites and Establishes the Therapeutic Effect Prediction Nomogram Among CP/CPPS Patients Who Respond or Do Not Respond to LiST. Frontiers in Immunology, $0,13,1$	2.2	1
68	A novel frameshift PKD1 mutation in a Chinese patient with autosomal dominant polycystic kidney disease and azoospermia: A case report. Experimental and Therapeutic Medicine, 2019, 17, 507-511.	0.8	0
69	Nanotoxicity: Harnessing Calciumâ€Oxalate―(CaOxâ€) Nanocrystal―nduced Prodeath Autophagy for Attenuating Human Renal Proximal Tubular Epithelial Cell Injury (Part. Part. Syst. Charact. 8/2019). Particle and Particle Systems Characterization, 2019, 36, 1970022.	1.2	0
70	MP79-14 LNCRNA-P21 ALTERS THE ANTIANDROGEN ENZALUTAMIDE-INDUCED PROSTATE CANCER NEUROENDOCRINE DIFFERENTIATION VIA MODULATING THE EZH2/STAT3 SIGNALING. Journal of Urology, 2020, 203, .	0.2	0
71	Single-Cell Multiomics Analysis Presents the Landscape of the Peripheral Blood T-Cell Subsets in Human Chronic Prostatitis/Chronic Pelvic Pain Syndrome. SSRN Electronic Journal, 0, , .	0.4	0
72	MP17-19 RECRUITED T CELLS PROMOTE THE BLADDER CANCER METASTASIS VIA UP-REGULATION OF THE ESTROGEN RECEPTOR β/IL-1/C-MET SIGNALS. Journal of Urology, 2020, 203, .	0.2	0

#	Article	IF	CITATIONS
73	Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer. Urologia Internationalis, 2022, , 1-9.	0.6	0
74	Development and external validation of a nomogram for predicting renal function based on preoperative data from in-hospital patients with simple renal cysts. Journal of International Medical Research, 2022, 50, 030006052210870.	0.4	0